Bionovo says study shows benefits of selective estrogen receptor compounds in menopause symptoms

By Lisa Kerner

Charlotte, N.C., Aug. 7 - Bionovo, Inc. said study results show the potential benefits and safety of selective estrogen receptor (ER) beta compounds in the treatment of menopausal symptoms.

The compounds, or anthraquinones, are isolated from Rheum palmatum, one of the botanical agents in the company's lead candidate, MF101, according to a company news release.

Benefits of the compounds include ER beta selective activity without the increased risk of breast cancer tumor formation or in-vivo uterine proliferation.

MF101, an ER-beta selective agonist, is designed for the treatment of vasomotor symptoms such as hot flashes and night sweats in postmenopausal women.

A multi-center, phase 2, double-blind, placebo-controlled, randomized clinical trial of MF101 in up to 180 postmenopausal women is underway at six sites throughout the United States.

Scott Baggett, a member of Bionovo's chemistry team, will present the results in a poster at the 47th Annual Meeting of the American Society of Pharmacognosy, in Arlington, Va.

Bionovo is an Emeryville, Calif., drug development company focusing on novel pharmaceutical agents for cancer and women's health.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.